London
· Delayed Price · Currency is GBP · Price in USD Centessa Pharmaceuticals Statistics
Total Valuation
Centessa Pharmaceuticals has a market cap or net worth of GBP 1.79 billion. The enterprise value is 1.43 billion.
| Market Cap | 1.79B |
| Enterprise Value | 1.43B |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.08% |
| Shares Change (QoQ) | +6.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 90.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 4.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.91 |
| EV / Sales | 257.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.74 |
Financial Position
The company has a current ratio of 21.52, with a Debt / Equity ratio of 0.17.
| Current Ratio | 21.52 |
| Quick Ratio | 21.15 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.65 |
| Interest Coverage | -15.88 |
Financial Efficiency
Return on equity (ROE) is -42.52% and return on invested capital (ROIC) is -21.80%.
| Return on Equity (ROE) | -42.52% |
| Return on Assets (ROA) | -20.47% |
| Return on Capital (ROIC) | -21.80% |
| Revenue Per Employee | 68,174 |
| Profits Per Employee | -1.60M |
| Employee Count | 76 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 16.86 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 51.16 |
| Average Volume (20 Days) | 248 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.48 |
Income Statement
In the last 12 months, Centessa Pharmaceuticals had revenue of GBP 5.11 million and -120.32 million in losses. Loss per share was -1.14.
| Revenue | 5.11M |
| Gross Profit | 5.11M |
| Operating Income | -120.61M |
| Pretax Income | -118.13M |
| Net Income | -120.32M |
| EBITDA | -120.35M |
| EBIT | -120.61M |
| Loss Per Share | -1.14 |
Balance Sheet
The company has 386.81 million in cash and 63.21 million in debt, giving a net cash position of 323.61 million.
| Cash & Cash Equivalents | 386.81M |
| Total Debt | 63.21M |
| Net Cash | 323.61M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 372.41M |
| Book Value Per Share | 2.83 |
| Working Capital | 404.35M |
Cash Flow
In the last 12 months, operating cash flow was -97.22 million and capital expenditures -46,258, giving a free cash flow of -97.27 million.
| Operating Cash Flow | -97.22M |
| Capital Expenditures | -46,258 |
| Free Cash Flow | -97.27M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -2,358.86% |
| Pretax Margin | -2,310.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Centessa Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.08% |
| Shareholder Yield | -11.08% |
| Earnings Yield | -6.74% |
| FCF Yield | -5.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Centessa Pharmaceuticals has an Altman Z-Score of 3.69.
| Altman Z-Score | 3.69 |
| Piotroski F-Score | n/a |